Stifel cuts Almonty Industries stock price target on shipment delays

Stifel reduced its price target on Almonty Industries (NASDAQ:ALM) to $21 from $25, citing shipment delays for its Sangdong projects. The stock has fallen 50% since September, trading at $8.83. Despite the setback, Stifel maintains a Buy rating, noting the company's strong balance sheet and role in meeting Western tungsten demand. Other analysts have mixed ratings and targets, ranging from $13 to $33. Almonty recently announced a tungsten offtake agreement with a Sandvik Group subsidiary.

Original reporting
Published Oct 20, 2026, 12:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ALM
Bearish
high confidence
Mentioned
$ALM
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALMBearishMed
01

Why it matters

The price‑target reduction reflects revised shipment timelines, reinforcing a bearish short‑term outlook.

02

Market read

ALM’s share price reacted sharply to the analyst downgrade, making it a near‑term trading opportunity.

03

What to watch

Potential upside from the new offtake agreement with Sandvik Group and high tungsten prices.

Relevance 6/10Novelty 6/10Timing: today

Background

Almonty Industries recently completed its U.S. IPO and returned to Nasdaq; multiple analysts have issued new targets.

Company-level read

Ticker impact

$ALMBearishHigh confidence
Context

Stifel lowered its price target for Almonty Industries to $21, citing shipment delays, and the stock fell 10% on the same day.

Expected impact

likely further decline as investors price in weaker shipment timelines

Evidence & confidence

Analyst downgrade with a concrete new target and a 10% price drop indicates fresh negative sentiment.

Market effects

Tungsten producers may see broader scrutiny as shipment delays raise supply concerns.

South Korean mining sector could face short-term pressure from the Sangdong delay.

Limited to commodity‑focused investors; no broad market effect.

Counterpoint

Despite the target cut, the stock may be oversold and could rebound if shipments resume on schedule.

Key entities

  • Stifel

    Reduced ALM price target to $21.

  • Almonty Industries

    Tungsten producer facing shipment delays at Sangdong projects.

Related articles

$ALMMed

Defense Stockpile Orders Send Explorers Back to Old Tungsten Camps

The U.S. Defense Logistics Agency awarded a $2B contract for tungsten supplies, with a $450M investment from the Department of War. GoldHaven Resources (CSE: GOH) completed drilling at its Kuhn tungsten-skarn target, intersecting skarn mineralization in two locations. Almonty Industries (NASDAQ: ALM) began commercial operations at its Sangdong plant, with 90% of Phase I production contracted. Guardian Metal (NYSE: GMTL) reported drilling results from its Tempiute project.

$ELMTMed

Technology Metals Report (10.04.2026): A Summit Without a Rare Earth Deal Leaves the West Buying Its Way to Supply

The U.S. and China failed to reach a rare earth supply deal during Xi Jinping's visit, leaving the West to secure supplies. Rare earth exports from China to the U.S. declined, with prices showing mixed trends. Elmet Group and Almonty Industries are expanding tungsten production. Glencore will partner with the U.S. strategic minerals reserve. Eramet plans to expand lithium production in Argentina. Processing capacity is also increasing, with Korea Zinc planning a U.S. smelter.

$ALMMed

Almirall, S.A.: Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026

Almirall, S.A. (ALM) presented new clinical data at EADV 2026, showcasing advances in dermatology treatments. Key findings include sustained improvements in atopic dermatitis with lebrikizumab and benefits in psoriasis with tildrakizumab. The company also highlighted its commitment to medical dermatology through sponsorship and awareness campaigns.

$ALMMed

Almonty Industries ALM Stock Rallies On Tungsten Breakout

Almonty Industries (NASDAQ: ALM) stock rose 11.09% on positive tungsten market news and project progress. The company reported $42.99M in quarterly revenue, $1.22B in cash, and a share buyback plan. ALM secured inspection certificates for its Sangdong project in South Korea and expanded operations in Rwanda, positioning itself as a key tungsten supplier outside China.